HALIFAX, March 21 /PRNewswire-FirstCall/ - MedMira Inc., ("MedMira") (TSX
Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid
diagnostic solutions, announced today that it has received an order for 10,000
MiraWell(R) Rapid HIV Tests (MiraWell(R) HIV) from its Middle East
distributor, Spree Trading, a member of the Shawwa Group International, which
is a multibillion-dollar global corporation with healthcare and diagnostic
sales divisions. These tests are destined for the Dubai market in the United
Arab Emirates (UAE), where they will be sold to immigration services,
hospitals and other healthcare facilities providing rapid HIV testing.
"We believe the UAE market and the Middle East region generally hold a
great deal of potential for the sale of MedMira's products," said Stephen
Sham, chairman and CEO, MedMira. "Spree Trading's aggressive marketing plans
and healthcare experience are key to capitalizing on sales of our products in
this growing market."
In 2005, MedMira completed the registration process with the UAE Ministry
of Health. Spree Trading will be pursuing further product evaluations, tender
opportunities, and new sales channels for MedMira's full product line. MedMira
will work closely with Spree Trading to evaluate and seek new market
opportunities for other MedMira products including an over-the-counter (OTC)
rapid HIV test and rapid test for HIV/Hepatitis C (HCV) co-infections.
Sham continued, "The sophisticated healthcare system in the UAE will
enable MedMira to expand our product offering in the region to include OTC
tests and other, more advanced rapid diagnostic solutions."
MiraWell(R) HIV is the fastest flow-through rapid HIV test in the world,
providing results instantly. MedMira's rapid tests have a wide range of
applications including occupational exposures, labor & delivery and general
screening. When used for general screening purposes, rapid HIV tests can
provide significant value, especially in a market such as Dubai where
expatriates make up 80% of the population and must be tested for HIV every two
years as part of the visa renewal process.
MedMira is the leading global manufacturer and marketer of in vitro flow-
through rapid diagnostic tests. MedMira's tests provide reliable, rapid
diagnosis in just 3 minutes for the detection of human antibodies in human
serum, plasma or whole blood for diseases such as HIV and hepatitis C. The
United States FDA and the SFDA in the People's Republic of China have approved
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively.
MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used
in clinical laboratories, hospitals, and clinics where professional
counselling and patient treatment are immediately available.
The MiraCare(TM) Rapid HIV Antibody Test is available over-the-counter
(OTC) in pharmacies throughout Hong Kong and Macao Special Administrative
Regions, in the People's Republic of China. MiraCare(TM) is sold through
MedMira's distributor network to pharmacies, hospitals and laboratories in the
MedMira delivers rapid diagnostic solutions to healthcare communities
around the globe. Its corporate offices and manufacturing facilities are
located in Halifax, Nova Scotia, Canada with a representative office in
This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
For more information visit MedMira's website at www.medmira.com.
SOURCE MedMira Inc.